# Scientists Identify Sleep Apnea as Surprising Dementia Risk Factor
Researchers have identified a new dementia risk factor that operates independently of genetics: sleep apnea. The discovery shifts how scientists understand cognitive decline, revealing that breathing disruptions during sleep create pathways to brain damage that bypass hereditary risk entirely.
Sleep apnea interrupts breathing repeatedly throughout the night, fragmenting sleep and reducing oxygen flow to the brain. This nightly stress appears to accelerate the accumulation of tau and amyloid proteins, the hallmark toxic buildup associated with Alzheimer's disease. The connection emerges clearly in recent studies tracking sleep patterns and brain biomarkers in middle-aged and older adults.
What makes this finding valuable is its actionable nature. Unlike genetic predisposition, sleep apnea responds to treatment. Continuous positive airway pressure (CPAP) therapy, the gold standard treatment, restores normal breathing patterns and oxygen delivery during sleep. By treating sleep apnea before brain damage accumulates, people may prevent or delay cognitive decline.
The research matters for women specifically. Sleep apnea often goes underdiagnosed in women because symptoms differ from those in men. Women report fatigue and mood changes rather than the loud snoring more commonly associated with the condition. This diagnostic gap means many women remain untreated while their brains face nightly oxygen stress.
Signs of sleep apnea include gasping awake, daytime sleepiness that persists despite adequate sleep time, and pauses in breathing reported by sleep partners. A sleep study can confirm the diagnosis within one night.
For people concerned about dementia risk, addressing sleep apnea offers concrete prevention strategy. Discussing sleep quality and daytime fatigue with a doctor opens pathways to evaluation. If sleep apnea is present, treatment with CPAP or other devices can restore healthy sleep architecture and protect cognitive